Insight journal - Dealtalk

Bio news: QLT seeks to dispose of drug delivery business

Posted on 12 July 2012

Tags: , ,

QLT has retained Goldman Sachs to explore the sale or spin-out of QLT's Punctal Plug Delivery System (PPDS) and to determine whether the company should retain or explore opportunities to partner or sell its Visudyne business as reported by bio news.

In the interim, QLT is pleased to continue offering Visudyne as an important treatment option to patients in the United States as the bio news report suggests further.

Read the full release at QLT website (link no longer available)

 

Related

Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply